Lung cancer can co-opt genes that normally help a fetus develop and evade the mother's immune system. And while these ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic ...

Join us for a quick overview of BioNTech SE, a Biotechnology company whose shares moved 0.3% today. Here are some facts about ...

A healthy 36-year-old non-smoker from the UK, was misdiagnosed with anxiety for months before discovering he had terminal ...

Researchers from Guilin Medical University and collaborators investigated the potential role of ubiquitin-specific protease 4 (USP4) in the occurrence and development of lung adenocarcinoma.

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with ...